Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer

SUMMARY: Tucatinib is a highly selective, oral, reversible human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor approved for the treatment of metastatic HER2-positive breast cancer. While its established adverse effects include diarrhoea, hepatotoxicity, and palmar-plantar erythrodysesthesia, endocrine toxicities have not been described in the Summary of Product Characteristics (SPC) or published literature. We report a case of secondary adrenal insufficiency in a 73-year-old woman receiving Tucatinib in combination with Trastuzumab and Capecitabine. She developed worsening hyponatremia and biochemical evidence of central adrenal suppression without prior steroid or opioid exposure. Sodium normalized promptly with glucocorticoid replacement. Following discontinuation of Tucatinib, hypothalamic-pituitary-adrenal (HPA) axis function recovered, and steroid therapy was successfully withdrawn. This case highlights a previously unreported potential endocrine adverse effect of Tucatinib and underscores the importance of vigilance for adrenal dysfunction in patients receiving targeted therapies.

Authors

Institutions

Publication Details

Journal
Endocrine Oncology
Published
2026-11-20
DOI
https://doi.org/10.1530/eo-26-0050
Primary Topic
Adrenal Hormones and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer

M. Parton, Daniel L. Morganstein, Imane Boughazi, Chloe Chan
Endocrine Oncology
Adrenal Hormones and Disorders
article

Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer

M. Parton, Daniel L. Morganstein, Imane Boughazi, Chloe Chan
article en

Abstract

SUMMARY: Tucatinib is a highly selective, oral, reversible human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor approved for the treatment of metastatic HER2-positive breast cancer. While its established adverse effects include diarrhoea, hepatotoxicity, and palmar-plantar erythrodysesthesia, endocrine toxicities have not been described in the Summary of Product Characteristics (SPC) or published literature. We report a case of secondary adrenal insufficiency in a 73-year-old woman receiving Tucatinib in combination with Trastuzumab and Capecitabine. She developed worsening hyponatremia and biochemical evidence of central adrenal suppression without prior steroid or opioid exposure. Sodium normalized promptly with glucocorticoid replacement. Following discontinuation of Tucatinib, hypothalamic-pituitary-adrenal (HPA) axis function recovered, and steroid therapy was successfully withdrawn. This case highlights a previously unreported potential endocrine adverse effect of Tucatinib and underscores the importance of vigilance for adrenal dysfunction in patients receiving targeted therapies.

Endocrine Oncology
Royal Marsden Hospital (GB), Chelsea and Westminster Hospital (GB)
Good health and well-being
Adrenal Hormones and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer — M. Parton, Daniel L. Morganstein, et al. · Endocrine Oncology (2026) | TGRS Research Map | TGRS